NCT07422363 2026-03-19
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
National Cancer Institute (NCI)
NRG Oncology
NRG Oncology
Mayo Clinic
University of Oklahoma
Technische Universität Dresden
Mayo Clinic